Chinese cancer drug firm Akesobio’s US$330 million IPO – Hong Kong’s largest this year – is oversubscribed 639 times by city’s investors

The IPO is also Hong Kong’s largest so far this year, and is also its biggest in the broader health care sector after Pharmaron Beijing’s HK$5.3 billion flotation last November, according to Refinitiv …
( read original story …)